Vazalore is a prescription medication used to treat erectile dysfunction (ED) [1]. It is a first-in-class oral vasodilator designed to directly increase blood flow to the penis [1][2].
How does Vazalore work?
Vazalore functions by inhibiting the enzyme phosphodiesterase type 11 (PDE11) [1][3]. This inhibition leads to increased cyclic guanosine monophosphate (cGMP) levels within the smooth muscle cells of the penis [1]. The elevated cGMP promotes smooth muscle relaxation and vasodilation, which enhances blood flow and facilitates an erection in response to sexual stimulation [1][2]. Unlike other ED treatments, Vazalore's mechanism is not dependent on nitric oxide [1].
When can I expect Vazalore to be available?
Vazalore received approval from the U.S. Food and Drug Administration (FDA) in June 2023 and is expected to be available in the U.S. in early 2024 [1][4].
What are the potential side effects of Vazalore?
The most common side effects reported for Vazalore include headache, flushing, and changes in blood pressure [1].
How does Vazalore differ from other ED treatments like Viagra or Cialis?
Vazalore is the first oral ED treatment that works by directly increasing blood flow without relying on the body's nitric oxide pathway [1]. Existing oral ED medications, such as sildenafil (Viagra) and tadalafil (Cialis), are phosphodiesterase type 5 (PDE5) inhibitors, which work by enhancing the effects of nitric oxide [1][5]. Vazalore's distinct mechanism of action may offer an alternative for patients who have not responded well to PDE5 inhibitors [1].
Are there any safety concerns with Vazalore and blood pressure?
Vazalore can cause a temporary decrease in blood pressure [1]. Patients taking antihypertensive medications should consult their doctor before using Vazalore, as the combination may lead to an additive hypotensive effect [1].
Who is developing Vazalore?
Vazalore is being developed by Viatris Inc. [4].